Percutaneous Microwave Ablation: A Viable Local Therapy for Breast Cancer Involving the Skin/Nipple-Areola Complex?

Background This study aimed to evaluate the treatment feasibility and efficacy of ultrasound (US)-guided percutaneous microwave ablation (MWA) in patients with breast cancer involving the skin/ nipple-areola complex (NAC). Material and methods A retrospective study was conducted on 15 patients diagnosed with breast cancer with skin/NAC involvement between December 2017 and April 2023. Throughout hospitalization and subsequent follow-up, regular clinical examinations and comprehensive breast imaging were performed to monitor and assess treatment outcomes. Results The study included fifteen patients diagnosed with breast cancer involving the skin/NAC, with a mean patient age of 60 ± 14 years (range, 33 - 86 years). The mean tumor diameter involving the skin/NAC (n=16) was 5.4 ± 3.1cm (range, 1.0 - 13.0 cm). All patients achieved technique success and technique effectiveness, as confirmed by contrast-enhanced ultrasound combined with dynamic contrast-enhanced magnetic resonance imaging. Before MWA, four patients had breast cancer involving the skin, four had breast cancer involving NAC, and seven had both. Furthermore, five patients presented with skin ulceration/nipple loss. Following MWA, four patients developed both perilesional skin burn and nipple loss, while one patient experienced nipple loss. The median healing time was 3.7 months (range, 2 - 6 months). During a median follow-up of 33.5 months (range, 2 - 63 months), four patients experienced recurrence, and two patients died due to late-phase breast cancer and heart disease, respectively. Conclusions US-guided percutaneous MWA shows feasibility and efficacy for managing breast cancer involving the skin/NAC. This technique offers hope for improved therapeutic options and presents a potential alternative treatment approach for these challenging breast cancer patients.